MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Second Cancer Risk For Stem Cell Transplant Recipients

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Second Cancer Risk For Stem Cell Transplant Recipients

Second Cancer Risk For Stem Cell Transplant Recipients
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, especially if they were older at the time of transplant or received stem cells from a female donor, as per a new study. Published in the January 1, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-evaluated journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population. In addition, cancer risk almost quadruples for patients who were over 40 years old at the time of transplant or for patients who received stem cells from a female donor.

Myeloablative, allogeneic HSCT is an effective standard treatment for specific life-threatening diseases, such as leukemia or myelodysplastic syndrome, for which blood cell lineages (which originate principally in the bone marrow and circulate in the blood) are abnormal. Destroying the patient's own unhealthy stem cells in the bone marrow and replacing them with a compatible donor's stem cells offers the chance of cure for a disease that otherwise has a high mortality rate with non-transplant therapies. While the procedure can be lifesaving, it is linked to serious short-term adverse effects, such as mucostitis, infections, and liver vascular obstruction as well as the potential long-term complication of developing of a second, commonly solid cancer.

To estimate the risk and identify risk factors linked to this outcome, Genevieve Gallagher, M.D. and Donna L. Forrest, M.D. of the BC Cancer Agency and the University of British Columbia, retrospectively evaluated the medical records of 926 patients treated with myeloablative stem cell transplants over an 18-year period.

They observed that at their institution the 10-year occurence rate of second cancers in these patients was 3.1 percent. When nonmelanoma skin cancer and carcinoma in situ of the cervix were excluded, incidence was 2.3 percent. That risk was 1.85 times that of the general population. The median time to diagnosis was almost 7 years after transplant. The most usually reported second cancers were cancers of the skin (basal and squamous cell), lung, oral cavity, and colon.

Furthermore, data analysis showed that the risk more than tripled for patients who received their transplant when they were over 40 years of age. The study also identified a new risk factor: patients who received stem cells from a female donor had almost quadrupled the risk of a second solid cancer, a risk that further increased when the patient was male. "This observation has not been previously published in the literature and the explanation for this finding is uncertain," say the authors.

"Since the risk of developing a solid neoplasm post-allogeneic transplantation continues to increase with time," suggest the authors, "extended follow-up will be needed to more fully assess the incidence and risk factors for their development".


Posted by: Janet    Source




Did you know?
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, especially if they were older at the time of transplant or received stem cells from a female donor, as per a new study. Published in the January 1, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-evaluated journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population. In addition, cancer risk almost quadruples for patients who were over 40 years old at the time of transplant or for patients who received stem cells from a female donor.

Medicineworld.org: Second Cancer Risk For Stem Cell Transplant Recipients

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.